No selective inhibitor for the B type of monoamine oxidase (MAO) was known until we demonstrated that C-) Deprenil, developed by us in 1964, is a preferential inhibitor of the metabolism of benzylamine and metaiodobenzylamine. Thus it was this paper which introduced C-) Deprenil, the first highly selective inhibitor of MAO-B. [The SCI® indicates that this paper has been cited in over 215 publiC...

This study investigated the risk factors for freezing of gait (FOG) in the early stage of Parkinson disease in China, using a sample of 248 patients who were followed for 3 years. Part III of the Unified Parkinson Disease Rating Scale and the modified Hoehn-Yahr grading scale were used to evaluate the severity of motor symptoms. Nonmotor symptoms were assessed using the Hamilton Anxiety Rating ...

Parkinson's disease (PD) is the second most common neurodegenerative disease and the most treatable. Treatment of PD is symptomatic and generally focuses on the replacement or augmentation of levodopa. A number of options are available for treatment, both in monotherapy of early PD and to treat complications of advanced PD. This review focuses on rasagiline and selegiline, two medications that ...